CRMD Kaufman Beth Zelnick sells $641K worth of shares
Sep 12, 2025, 4:35 AM
0.00%
What does CRMD do
CorMedix is a pharmaceutical company based in New Jersey, focused on developing therapeutic products, notably DefenCath, an antimicrobial solution for preventing catheter-related bloodstream infections in kidney failure patients. The company went public in 2010 and has also sponsored research on taurolidine for rare pediatric tumors.
Kaufman Beth Zelnick sold 50,000 shares of CRMD on 9 September at $12.82 per share, worth a total of $641K. They now own 180,818 CRMD shares, or a 22% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.